What is the current Direct Acting Antivirals market size?

The Direct Acting Antivirals market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the Direct Acting Antivirals market?

Increasing disease prevalence and advances in antiviral therapy are key drivers of market growth.

What challenges does the Direct Acting Antivirals market face?

The market faces challenges from high development costs and strict regulatory requirements.

Which regions are the leaders in the Direct Acting Antivirals market?

North America and Europe are the leading regions in the Direct Acting Antivirals market.

Who are the top companies in the Direct Acting Antivirals market?

Top companies include Gilead, AbbVie, and Merck, which dominate the market landscape.

What future opportunities exist in the Direct Acting Antivirals market?

Emerging markets and innovative treatments offer future opportunities for market expansion.

How does technology impact the Direct Acting Antivirals market?

Advances in technology improve treatment efficacy and patient outcomes, driving market growth.

What is the current regulatory landscape for the Direct Acting Antivirals market?

The regulatory landscape is strict, with FDA and EMA guidelines governing market approvals.

Direct Acting Antivirals Industry Trends & Competitive Analysis 2033

Direct Acting Antivirals by Application (Hospital and Clinic, Pharmacy, Other), by Types (Pangenotypic, Genotype-Specific), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Direct Acting Antivirals Market Size | CAGR 10.2 Forecast 2033

Direct Acting Antivirals Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Direct Acting Antivirals Market Overview

The Direct Acting Antivirals market refers to the industry that develops and commercializes antiviral medications that directly target viral replication. As the Direct Acting Antivirals market size is expected to reach $24.5 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion driven by increasing demand for effective treatments against viral diseases, with key synonyms including antiviral therapeutics and viral infection treatments. The scope of this market encompasses various segments, including hepatitis C, hepatitis B, and respiratory syncytial virus treatments.

Loading chart…

The current Direct Acting Antivirals market size is estimated to be around $18.3 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033. Key macro drivers include advancements in biotechnology and pharmaceutical research, increasing patient awareness and government initiatives to combat viral diseases. The largest region for Direct Acting Antivirals is currently North America, while the fastest-growing region is expected to be the Asia-Pacific. Technology shifts, such as the development of novel antiviral compounds, regulations, including stringent safety protocols, and consumer behavior, driven by growing demand for effective treatments, are among the key forces shaping the industry.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences; AbbVie; Merck; Bristol Myers Squibb; Asegua Therapeutics; Ascletis Pharma; Kawin Technology; YiChang HEC ChangJiang Pharmaceutical; Sanhome Pharmaceutical; Chia Tai Tianqing Pharmaceutical; Cosunter pharmaceutical; Beijing Sihuan Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Direct Acting Antivirals market is poised for significant growth, driven by various factors. The market dynamics are influenced by a combination of growth drivers, restraints, opportunities, and challenges that shape the industry landscape.

Growth Drivers2 items

Increasing prevalence of viral diseases, such as hepatitis C and COVID-19, is driving the demand for Direct Acting Antivirals, thereby contributing to the growth of the market size. This trend is expected to continue, with the global Direct Acting Antivirals market size projected to expand at a significant rate during the forecast period.

Advances in technology and the development of novel Direct Acting Antivirals with improved efficacy and safety profiles are also fueling market growth, enabling companies to capitalize on the growing demand for effective treatments and driving the growth forecast for the industry.

Restraints2 items

High development costs and stringent regulatory requirements are major restraints in the Direct Acting Antivirals market, limiting the entry of new players and hindering the growth of existing ones. These factors can also impact the growth forecast and overall market size.

The presence of generic versions of Direct Acting Antivirals and patent expirations of key products can lead to decreased revenue for pharmaceutical companies, further constraining market growth and affecting the Direct Acting Antivirals market size.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies presents opportunities for companies to develop innovative Direct Acting Antivirals that cater to specific patient needs, driving growth and expansion in the market. This trend is expected to contribute to the growth forecast and Direct Acting Antivirals market size.

Emerging markets in Asia-Pacific and Latin America offer significant growth opportunities for Direct Acting Antivirals manufacturers, driven by improving healthcare infrastructure and rising demand for effective treatments, ultimately influencing the Direct Acting Antivirals market.

Challenges2 items

The Direct Acting Antivirals market faces challenges related to antiviral resistance, which can reduce the effectiveness of treatments and necessitate the development of new drugs, impacting the overall growth forecast and market size. Companies must invest in research and development to address this issue.

Ensuring affordable pricing and accessibility of Direct Acting Antivirals in low- and middle-income countries remains a significant challenge, requiring manufacturers to adopt strategic pricing models and collaborate with governments and healthcare organizations to expand market reach and drive growth in the Direct Acting Antivirals market.

Market Segmentation

Loading chart…

The Application segment of the Direct Acting Antivirals market is a crucial aspect of the Direct Acting Antivirals segmentation process. This segment is divided into subtypes, including the treatment of Hepatitis C, Hepatitis B, and other viral infections. The application segment contributes significantly to the overall market size, with each subtype having a distinct market share. For instance, the treatment of Hepatitis C accounts for a substantial share of the market, driven by the high prevalence of the disease and the availability of effective Direct Acting Antivirals.

The Types segment of the Direct Acting Antivirals market is another essential aspect of the market taxonomy. This segment is categorized into subtypes, including NS5A inhibitors, protease inhibitors, and polymerase inhibitors. Each subtype has a unique mechanism of action and is used to treat specific viral infections. The types segment plays a vital role in determining the overall market size, with each subtype having a distinct market share. Understanding the types segment is critical for stakeholders to develop effective strategies and make informed decisions.

Direct Acting Antivirals Segmentation Breakdown7 items

Application

Hospital and Clinic

Pharmacy

Other

Types

Pangenotypic

Genotype-Specific

Regional Insights

Loading chart…

The Direct Acting Antivirals market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of Direct Acting Antivirals, government initiatives, and rising investments in healthcare infrastructure.

Key drivers for North America include high adoption rates, favorable policies and regulations, and significant investments in research and development. In Europe, drivers include established healthcare infrastructure, ecosystem maturity, and demographic factors. Asia Pacific's growth is driven by increasing demand, government support, and expanding distribution networks. Latin America's growth is influenced by rising healthcare expenditure, improving infrastructure, and growing awareness. The Middle East & Africa region is driven by growing demand, investments in healthcare, and expanding patient population.

The regional forecast indicates that the Direct Acting Antivirals market will continue to grow, with each region contributing to the overall market growth. Understanding the key drivers and factors influencing each region is crucial for stakeholders to make informed decisions and capitalize on emerging opportunities.

Competitive Landscape

The Direct Acting Antivirals market is moderately consolidated, driven by a mix of global players and local companies. The Direct Acting Antivirals competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on pricing and distribution.

Companies in the Direct Acting Antivirals market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Common differentiation factors include technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to address these challenges and maintain their market position.

Gilead Sciences: regional expansion

AbbVie: innovation pipeline

Merck: premium pricing

Bristol Myers Squibb: local manufacturing

Asegua Therapeutics: OEM tie-ups

Ascletis Pharma: vertical integration

Key Direct Acting Antivirals Companies12 items

Gilead Sciences

AbbVie

Merck

Bristol Myers Squibb

Asegua Therapeutics

Ascletis Pharma

Kawin Technology

YiChang HEC ChangJiang Pharmaceutical

Sanhome Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Cosunter pharmaceutical

Beijing Sihuan Pharmaceutical

Market Ecosystem

The Direct Acting Antivirals ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where these inputs are integrated into final products; and downstream, where these products are distributed to end users. Value is created and captured at each stage, with participants interacting and influencing one another to drive the overall ecosystem forward.

Raw material suppliers — providing chemical compounds

Technology providers — developing antiviral formulations

OEMs/manufacturers — producing final pharmaceutical products

Distributors/channel partners — delivering products to healthcare providers

Service providers/after-sales — offering patient support and education

Regulators/standards bodies — overseeing safety and efficacy standards

End users/buyers — patients and healthcare providers prescribing and using antiviral treatments

In the Direct Acting Antivirals ecosystem, value flows through the interactions and interdependencies among these participants. Control points, such as regulatory approvals and reimbursement policies, influence the adoption of these treatments. Dependency risks, including input constraints and standards compliance, can impact the supply chain. Additionally, switching costs and partnerships between manufacturers and distributors can affect the ecosystem's dynamics. As part of a comprehensive value chain analysis, understanding these factors is crucial to navigating the intricacies of the Direct Acting Antivirals ecosystem, which can differ significantly by region due to varying regulatory frameworks and healthcare systems.

Recent Industry Insights

The Direct Acting Antivirals industry has witnessed significant developments over the last 12-18 months, shaping Direct Acting Antivirals industry trends. Recent partnerships, such as the collaboration between pharmaceutical companies to enhance antiviral drug development, have been instrumental in driving innovation. Furthermore, mergers and acquisitions, like the acquisition of a biotech firm by a leading pharmaceutical company, have expanded the market's capabilities. Additionally, the launch of new products and technologies has improved treatment options for various viral infections, while regulatory changes have ensured stricter safety and efficacy standards.

A notable shift in consumer trends has been observed, with an increasing demand for effective and convenient antiviral treatments. This has led to funding rounds and expansions, enabling companies to invest in research and development. As a result, the Direct Acting Antivirals market is poised for growth, with companies focusing on developing novel and targeted therapies to address emerging viral threats, ultimately influencing Direct Acting Antivirals industry trends.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Direct Acting Antivirals market outlook. The market attractiveness is moderate, driven by the increasing prevalence of viral diseases and the availability of effective treatments. The competitive intensity is high, with multiple players vying for market share. The long-term outlook is positive, with ongoing innovation in the Direct Acting Antivirals space expected to drive growth.

The innovation landscape is characterized by the development of new therapies and treatment options, which is expected to improve the demand–supply balance. However, key risk factors such as regulatory changes and patent expirations may impact the market. Overall, decision-makers should be aware of these factors when navigating the Direct Acting Antivirals market.

12 items

1. Executive Summary

2. Direct Acting Antivirals Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Direct Acting Antivirals Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Direct Acting Antivirals Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Direct Acting Antivirals Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Direct Acting Antivirals Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Direct Acting Antivirals Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Direct Acting Antivirals Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Direct Acting Antivirals Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Direct Acting Antivirals Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Direct Acting Antivirals Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Direct Acting Antivirals Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Direct Acting Antivirals Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Direct Acting Antivirals Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Direct Acting Antivirals Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Direct Acting Antivirals Market Competition by Key Manufacturers

9.1. Global Direct Acting Antivirals Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Direct Acting Antivirals: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Gilead Sciences

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. AbbVie

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Merck

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bristol Myers Squibb

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Asegua Therapeutics

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ascletis Pharma

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Kawin Technology

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. YiChang HEC ChangJiang Pharmaceutical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Sanhome Pharmaceutical

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Chia Tai Tianqing Pharmaceutical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Cosunter pharmaceutical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Beijing Sihuan Pharmaceutical

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Direct Acting Antivirals Market

Figure 4: Global Direct Acting Antivirals Market: Drivers

Figure 5: Global Direct Acting Antivirals Market: Challenges

Figure 6: Global Direct Acting Antivirals Market: Trends

Figure 7: Global Direct Acting Antivirals Market: Opportunity

Figure 8: Global Direct Acting Antivirals Market: Restraint

Figure 9: Global Direct Acting Antivirals Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Direct Acting Antivirals Market Value (USD Million) By Region

Figure 19: Global Direct Acting Antivirals Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Direct Acting Antivirals Market Value (USD Million) By Region

Figure 27: Global Direct Acting Antivirals Market Share (%) By: Regions (2032)

Figure 28: Global Direct Acting Antivirals Market Volume (K) By Region

Figure 29: Global Direct Acting Antivirals Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Direct Acting Antivirals Market Value (USD Million) By Region

Figure 37: Global Direct Acting Antivirals Market Share (%) By: Regions (2032)

Figure 38: Global Direct Acting Antivirals Market Volume (K) By Region

Figure 39: Global Direct Acting Antivirals Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Direct Acting Antivirals Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Direct Acting Antivirals Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Direct Acting Antivirals Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Direct Acting Antivirals Market Value (USD Million) By Region

Table 14: Global Direct Acting Antivirals Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Direct Acting Antivirals Market Volume (K) By Region

Table 31: Global Direct Acting Antivirals Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Direct Acting Antivirals Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Direct Acting Antivirals Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Direct Acting Antivirals Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Gilead Sciences Basic Information And Sales Area

Table 52: Gilead Sciences. Products Portfolio

Table 53: AbbVie Basic Information And Sales Area

Table 54: AbbVie. Products Portfolio

Table 55: Merck Basic Information And Sales Area

Table 56: Merck. Products Portfolio

Table 57: Bristol Myers Squibb Basic Information And Sales Area

Table 58: Bristol Myers Squibb. Products Portfolio

Table 59: Asegua Therapeutics Basic Information And Sales Area

Table 60: Asegua Therapeutics. Products Portfolio

Table 61: Ascletis Pharma Basic Information And Sales Area

Table 62: Ascletis Pharma. Products Portfolio

Table 63: Kawin Technology Basic Information And Sales Area

Table 64: Kawin Technology. Products Portfolio

Table 65: YiChang HEC ChangJiang Pharmaceutical Basic Information And Sales Area

Table 66: YiChang HEC ChangJiang Pharmaceutical. Products Portfolio

Table 67: Sanhome Pharmaceutical Basic Information And Sales Area

Table 68: Sanhome Pharmaceutical. Products Portfolio

Table 69: Chia Tai Tianqing Pharmaceutical Basic Information And Sales Area

Table 70: Chia Tai Tianqing Pharmaceutical. Products Portfolio

Table 71: Cosunter pharmaceutical Basic Information And Sales Area

Table 72: Cosunter pharmaceutical. Products Portfolio

Table 73: Beijing Sihuan Pharmaceutical Basic Information And Sales Area

Table 74: Beijing Sihuan Pharmaceutical. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Direct Acting Antivirals Market Value (USD Million) By Region

Table 84: Global Direct Acting Antivirals Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global Direct Acting Antivirals Market Volume (K) By Region

Table 101: Global Direct Acting Antivirals Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Direct Acting Antivirals Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences; AbbVie; Merck; Bristol Myers Squibb; Asegua Therapeutics; Ascletis Pharma; Kawin Technology; YiChang HEC ChangJiang Pharmaceutical; Sanhome Pharmaceutical; Chia Tai Tianqing Pharmaceutical; Cosunter pharmaceutical; Beijing Sihuan Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options